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Abstract
The process of vascular calcification shares many similarities with that of physiological skeletal mineralization, and involves the deposition of
hydroxyapatite crystals in arteries. However, the cellular mechanisms responsible have yet to be fully explained. Bone morphogenetic protein
(BMP-9) has been shown to exert direct effects on both bone development and vascular function. In the present study, we have investigated
the role of BMP-9 in vascular smooth muscle cell (VSMC) calcification. Vessel calcification in chronic kidney disease (CKD) begins pre-dialysis,
with factors specific to the dialysis milieu triggering accelerated calcification. Intriguingly, BMP-9 was markedly elevated in serum from CKD
children on dialysis. Furthermore, in vitro studies revealed that BMP-9 treatment causes a significant increase in VSMC calcium content, alkaline
phosphatase (ALP) activity and mRNA expression of osteogenic markers. BMP-9-induced calcium deposition was significantly reduced follow-
ing treatment with the ALP inhibitor 2,5-Dimethoxy-N-(quinolin-3-yl) benzenesulfonamide confirming the mediatory role of ALP in this process.
The inhibition of ALK1 signalling using a soluble chimeric protein significantly reduced calcium deposition and ALP activity, confirming that
BMP-9 is a physiological ALK1 ligand. Signal transduction studies revealed that BMP-9 induced Smad2, Smad3 and Smad1/5/8 phosphoryla-
tion. As these Smad proteins directly bind to Smad4 to activate target genes, siRNA studies were subsequently undertaken to examine the
functional role of Smad4 in VSMC calcification. Smad4-siRNA transfection induced a significant reduction in ALP activity and calcium deposi-
tion. These novel data demonstrate that BMP-9 induces VSMC osteogenic differentiation and calcification via ALK1, Smad and ALP dependent
mechanisms. This may identify new potential therapeutic strategies for clinical intervention.
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Introduction
Arterial medial calcification (AMC), a hallmark of disease in
patients with end-stage kidney disease, is highly correlated with
elevated serum phosphate levels and cardiovascular mortality [1,
2]. AMC is recognized as an active, tightly regulated process, shar-
ing many similarities with physiological bone formation [3], and
involves the deposition of hydroxyapatite crystals in arteries.
Indeed vascular smooth muscle cells (VSMCs), the predominant
cell type involved in AMC, can undergo transdifferentiation to a
chondrocytic, osteoblastic and osteocytic phenotype in a calcified
environment [3, 4].
Bone morphogenetic proteins (BMPs) constitute a group of sig-
nalling factors that orchestrate embryonic patterning in development
and contribute to post-natal tissue remodelling. Over 20 identified
BMP ligands are recognized by type I and type II serine-threonine
kinase BMP receptors [5]. Ligand binding induces constitutively
active BMP type II receptors to transphosphorylate BMP type I
receptors, which in turn phosphorylate the intracellular BMP effector
proteins, Smad 1/5/8. Signalling through Smad1/5/8 activation medi-
ates the principal effects of BMPs, although activation of additional
pathways may further refine cellular effects [6].
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Bone morphogenetic proteins are vital regulators in orthotopic bone
formation, and their localization at sites of vascular calcification raises
the question of their role in this pathological process. The concept that
BMPs mediate vascular calcification is supported by the knowledge that
smooth muscle-targeted overexpression of BMP-2 accelerates vascular
calcification in atherogenic mice [7]. Furthermore, loss of matrix Gla
protein (MGP), an endogenous BMP inhibitor, causes extensive calcifi-
cation of elastic and muscular arteries [8], suggesting that regulation
of BMP activity is essential for maintaining a normal vessel media.
As one of the least studied BMPs, BMP-9 has to date been shown
to regulate the cholinergic phenotype of embryonic basal forebrain
cholinergic neurons [9], controlling iron homoeostasis [10] and modu-
lating key enzymes of lipid metabolism [11]. A number of studies have
also established BMP-9 as a key regulator of angiogenesis in endothe-
lial cells [12–14]. Of direct relevance to this study, BMP-9 has recently
been identified as one of the most osteogenic BMPs, regulating several
downstream targets during BMP-9-induced osteoblast differentiation
including Runx2, osteocalcin and Tissue-nonspecific alkaline phospha-
tase (ALP) [15]. However, the role of BMP-9 in regulating the pheno-
typic transdifferentiation of VSMCs during calcification is unknown
and warrants investigation. Therefore, we have undertaken clinical
analyses in conjunction with in vitro VSMC calcification studies to
identify BMP-9 and the BMP signalling pathway as a potential thera-
peutic target for modifying vascular calcific disease.
Materials and methods
Ethics statement
For clinical studies, informed written consent was obtained from all par-
ents or caregivers and children, where appropriate. The study was
approved by the local research ethics committee. All animal experiments
were approved by The Roslin Institute’s Animal Users Committee and
the animals were maintained in accordance with Home Office guidelines
for the care and use of laboratory animals.
Clinical samples
Blood samples were obtained from 10 children in pre-dialysis chronic kid-
ney disease (CKD) stage V (estimated glomerular filtration rate <15 ml/
min./1.73 m2) and 10 children on haemodialysis. Samples were collected
at a routine clinic visit or before a mid-week session of haemodialysis. To
keep the groups free of confounding pro-atherosclerotic risk factors, chil-
dren with underlying inflammatory disorders, vasculitis, diabetes, dyslip-
idaemia or smokers were excluded. Serum biochemical parameters
(calcium, phosphate and high sensitivity C-Reactive Protein (hs-CRP)) and
BMP-9 concentrations (R&D Systems, Abingdon, UK) were determined.
Materials
Recombinant mouse BMP-9 and Activin receptor-like kinase-1 fusion pro-
tein (ALK1-Fc) were from R&D Systems. The ALP inhibitor 2,5-Dimeth-
oxy-N-(quinolin-3-yl) benzenesulfonamide (DBS) was from Merk KGaA
(Darmstadt, Germany). Antibodies to phosphorylated Smad1/5/8, Smad2,
Smad3, Akt (ser 473) and Erk1/2 Map kinase (Thr202-/Tyr204) and to
total Smad1/5/8, Smad2, Smad3, Smad4, Akt and Erk1/2 Map kinase
were from Cell Signaling Technology (Beverly, MA, USA). Antibodies to
anti-alpha-smooth muscle actin (SMA) and anti-CD31 were from Sigma-
Aldrich (Poole, UK) and Abcam (Cambridge, UK), respectively. a-MEM
medium, Fetal Bovine Serum (FBS), Gentamicin, Alexa Fluor@488 goat-an-
timouse and Alexa Fluor@594 goat-anti rabbit antibodies were obtained
from Invitrogen (Paisley, UK). Collagenase type II was from Worthing-
ton Biochemical Corporation (Lakewood, NJ, USA). Laminin was from
Sigma-Aldrich. Tissue culture flasks were from Greiner Bio-one (Fric-
kenhausen, Baden-Wurttemberg, Germany).
Preparation of primary murine VSMCs
Primary VSMCs were prepared from 5-week old wild-type (WT) C57BL/
6 mice and cultured in growth medium as previously described [4, 16].
Briefly, after careful removal of adventitia, the aorta was cut open to
expose endothelial layer under a dissection microscope. Tissues from
eight animals were pooled together and incubated with 1 mg/ml trypsin
for 10 min to remove any remaining adventitia and endothelium. After a
further overnight incubation at 37°C in a humidified atmosphere of 95%
air/5% CO2 in growth medium consisting of a-MEM supplemented with
10% FBS and 1% gentamicin, tissues were digested with 425 U/ml col-
lagenase type II for 5 hrs. Medial cells were released and cell suspen-
sion was centrifuged at 2000 9 g for 5 min. The cell pellet was
washed and re-suspended in the above mentioned growth medium. Iso-
lated VSMCs were cultured with growth medium for two passages in
T25 tissue culture flasks coated with 0.25 lg/cm2 laminin to promote
maintenance of the contractile differentiation state [17].
Induction of calcification
Primary VSMCs were seeded in growth medium at a density of
1.5 9 104/cm2 in multi-well plates. Calcification was induced as previ-
ously described [16]. In brief, cells were grown to confluence (day 0)
and switched to calcification medium, which was prepared by adding
inorganic phosphate (a mixture of NaH2PO4 and Na2HPO4, pH 7.4)
(Sigma-Aldrich), to reach a final concentration of 3 mM phosphate.
VSMCs were incubated for up to 14 days in 95% air/5% CO2 and
medium was changed every third/fourth day. Recombinant mouse
BMP-9, ALK1-Fc or 3 lM ALP inhibitor was added at day 0.
Determination of calcification
Calcium deposition was quantified as previously described [16]. Briefly,
cells were rinsed twice with PBS and decalcified with 0.6 N HCL at
room temperature for 24 hrs. Free calcium was determined colorometri-
cally by a stable interaction with phenolsulphonethalein using a com-
mercially available kit (Randox Laboratories Ltd., County Antrim, UK)
and corrected for total protein concentration (Bio-Rad Laboratories Ltd,
Hemel Hempstead, UK).
Calcium deposition was also evaluated by alizarin red staining as pre-
viously described [16, 18]. Cells were washed twice with PBS, fixed in
4% paraformaldehyde for 5 min at 4°C, stained with 2% alizarin red
(pH 4.2) for 5 min at room temperature and rinsed with distilled water.
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Alkaline phosphatase activity
Alkaline phosphatase activity from whole cell lysates was assayed as pre-
viously described [4, 16]. Cells were washed with PBS twice, solubilized
with 0.2% Triton X-100 in 0.9% NaCl and assayed for ALP activity.
Enzyme activity was determined by measuring the cleavage of 10 mM
p-nitrophenyl phosphate (pNPP) at 410 nm using a commercially avail-
able kit (Thermo Trace, Melbourne, Australia). Values were normalized to
total protein levels, as assessed by the Bio-Rad protein assay reagent
(Bio-Rad Laboratories, Hertfordshire, UK), and gamma globulin was used
as standard. Total ALP activity was expressed as nmoles pNPP hydroly-
sed/min./mg protein.
Analysis of gene expression
RNA was extracted using RNeasy total RNA (Qiagen Ltd, Crawley, West
Sussex, UK), according to the manufacturer’s instructions. RNA was
reverse transcribed and specific cDNAs were semi-quantified by end-
point PCR or quantified by real-time PCR using the SYBR green detec-
tion method as previously reported [4, 16]. Primers were obtained from
Eurofins MWG Biotech (Ebersberg, Germany), Qiagen and Primer
Design (Southampton, UK), with available sequences provided in the
online Data Supplement (Table S1).
Western blotting
Cultured cells were harvested in RIPA buffer (Sigma-Aldrich) contain-
ing ‘complete’ protease inhibitor cocktail according to manufacturer’s
instructions (Roche, East Sussex, UK). Western blotting was per-
formed as previously described [19]. Nitrocellulose membranes were
probed overnight at 4°C with anti-sclerostin antibody (R&D Systems)
or BMP-9 primary antibody [Abcam, 1:1000 dilution in 5% bovine
serum albumin (BSA)], washed in TBST and incubated with anti-goat
or anti rabbit IgG-peroxidase respectively (DAKO, Glostrup, Denmark)
for 1 hr (1:1000 dilution in 5% milk). The immune complexes were
visualized using enhanced chemi-luminescence (ECL) (GE Healthcare,
Buckinghamshire, UK). Membranes were then washed in ‘stripping
buffer’ (Pierce, Rockford, Il, USA) and re-probed for 1 hr for b-actin
expression (1:5000 dilution in 5% milk; anti b-actin clone AC15;
Sigma-Aldrich).
Cell signalling immunoblotting
Vascular smooth muscle cells were grown to confluence and serum
starved for 24 hrs. Cells were treated with 0–50 ng/ml recombinant
mouse BMP-9 for 30 min or 50 ng/ml BMP-9 for 0–60 min (R&D
Systems). Cells were lysed in PhosphoSafe extraction buffer (Merck
Biosciences Ltd, Nottingham, UK) containing ‘Complete’ protease
inhibitor cocktail (Roche) according to manufacturer’s instructions for
cell signalling studies. Western blotting was performed as previously
described [4]. Nitrocellulose membranes were probed overnight at
4°C with the relevant primary rabbit antibody (phospho-Smad1/5/8,
phospho-Smad2, phospho-Smad3, total Smad2, total Smad3, Smad4,
phospho-Akt (ser 473), total Akt, phospho-Erk1/2 Map kinase (Thr202-/
Tyr204) and total Erk1/2 Map kinase or total Smad1/5/8). The
membranes were then incubated with anti rabbit IgG-peroxidase (Cell
Signalling Technology) for 1 hr (1:1000 dilution in 5% milk). The
immune complexes were visualized using enhanced chemi-luminescence
(ECL) Western Blotting Detection System (GE Healthcare, Buckingham-
shire, UK).
Transfection assays
Vascular smooth muscle cells were seeded in 12-well plates at a density
of 80,000 cells/well and transfected with Allstars Negative Control siR-
NA (20 nM; Scrambled siRNA (Qiagen Ltd)) or Smad4 siRNA (20 nM;
Qiagen Ltd) with Hyperfect transfection reagent (Qiagen Ltd), according
to manufacturer’s instructions. Cells were used for experiments 48 or
96 hrs after transfection. The knock-down efficiency of Smad4 was veri-
fied by qRT-PCR and western blotting. For long-term VSMC calcification
assay, cells were re-transfected at day 4 and cultured in the presence
of the calcification medium for up to 9 days.
Fluorescent immunocytochemical staining
Vascular smooth muscle cells were seeded on glass coverslips in 12-
well plates at a density of 50,000 cells/well. Following confluence,
VSMCs were serum-restricted for 24 hrs and stimulated with 0–50 ng/
ml recombinant mouse BMP-9 for 30 min. Cells were fixed with 4%
paraformaldehyde and washed with PBS. The fixed cells were permea-
bilized with 0.3% Triton X-100 (Sigma-Aldrich) and incubated with
anti-alpha-SMA, anti-CD31, or anti-phospho-Smad1/5/8 antibody over-
night at 4°C. After washing, cells were incubated with Alexa Fluor@488
goat-anti mouse antibody or Alexa Fluor@594 goat-anti rabbit antibody
for 1 hr in the dark. Glass coverslips were mounted onto slides with
ProlongGold Anti-Fade Reagent contained DAPI (Invitrogen). Fluores-
cence signal was detected under a Leica fluorescence microscope
(Milton Keynes, UK).
Flow cytometric analysis
Vascular smooth muscle cell suspensions were obtained by trypsinisa-
tion (0.25% Trypsin-EDTA, Invitrogen), and washed with PBS twice.
Fig. 1 Assessment of bone morphogenetic protein (BMP-9) in serum
from CKD dialysis patients. BMP-9 concentrations (pg/ml) in pre-dialy-
sis (n = 10) and dialysis (n = 9) serum from children with CKD.
ª 2014 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
3
J. Cell. Mol. Med. Vol XX, No X, 2014
Cells were incubated with isotype control or anti-CD31 antibody (1:100
dilution, Abcam) for 30 min at room temperature. Cells were washed
and incubated with Alexa Fluor@594 goat-anti rabbit antibodies (1:1000
dilution, Invitrogen) for 30 min in the dark. After wash, cells were
analysed with a BD Fortessa (BD Biosciences. Oxford, UK). Data were
evaluated using FlowJo v7.5.5 (Tree Star, Ashland, OR, USA).
Table 1 Clinical and biochemical features of the pre-dialysis and dialysis groups
Serum Ca (mmol/l) PO4 (mmol/l) Ca 3 PO4 hs-CRP (mg/l)
Pre-dialysis (n = 10) 2.40 (0.04) 1.55 (0.06) 3.71 (0.17)
Dialysis (n = 9) 2.46 (0.02) 1.64 (0.05) 4.04 (0.13) 13.48 (3.25)
A
B
C
Fig. 2 High Pi induces the calcification of
VSMCs. (A) Immunofluorescence staining
of murine primary VSMCs demonstrates
positive staining for the smooth muscle
cell marker smooth muscle actin (SMA;
Green) and negative staining for the endo-
thelial cell marker, CD31. (B) FACs analy-
sis further confirmed only 1.56% of
isolated cells positively stained for CD31.
(C) Alizarin red staining and Quantification
of calcification by HCL leaching (n = 3) in
VSMCs cultured with high phosphate
(3 mM Pi; filled bar) or control (1 mM Pi;
white bar) medium (n = 5). Results are
presented as mean  SEM. ***P < 0.001
compared with control; scale bar =
100 lm.
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BMP-9 ELISA
Human serum of 100 ll was used to measure BMP-9 concentrations
using the human BMP-9 DuoSet Kit (R&D Systems) according to manu-
facturer’s instructions. BMP-9 recombinant protein standards ranging
from 0 to 1000 pg/ml were prepared in 1% BSA in PBS. The plate was
read at a dual wave length of 450 and 540 nm using a BioTek plate
reader (BioTek, Bedfordshire, UK). BMP-9 concentration was determined
by reading from the standard curve, which was created by Gen5 soft-
ware (BioTek) using a four parameter logistic (4-PL) curve-fit.
Statistics
Data are presented as the means  SEM. Statistical analysis was deter-
mined by General Linear Model Analysis incorporating pairwise compar-
isons, the Student’s t-test using Minitab 16 (Minitab Inc, Coventry, UK).
P < 0.05 was considered to be significant. N = x indicates the number
of different wells of a representative cell culture experiment. Each cell
culture experiment was repeated at least twice.
Results
Increased serum BMP-9 in CKD dialysis patients
BMP-9 was markedly elevated in serum from children on haemodialy-
sis (234% increase compared to pre-dialysis CKD; P < 0.001; Fig. 1).
No significant differences in calcium, phosphate or calcium 9 phos-
phate product were noted (Table 1). Furthermore, no correlation
between BMP-9 concentration and high sensitivity C-Reactive Protein
(hs-CRP) were seen (Table 1). These data are the first to show that
BMP-9 is elevated in dialysis patients.
Up-regulation of BMP-9 during the VSMC
calcification process
We confirmed that murine primary VSMCs isolated in the present
study were free from endothelial contamination. Cells were negative
A B
C D E
Fig. 3 Up-regulated bone morphogenetic
protein (BMP-9) expression during the
calcification process of VSMCs. VSMCs
were cultured with high phosphate (3 mM
Pi; filled bar) or control (1 mM Pi; white
bar) medium (n = 5) by 7 and 14 days.
Fold change in the mRNA expression of
(A) Bmp2, (B) Runx2 and (C) PiT-1. (D)
BMP-9 protein was expressed by VSMCs
at 0 day. (E) Fold change in the mRNA
expression of BMP-9. Results are pre-
sented as mean  SEM. ***P < 0.001
compared with control.
A B
Fig. 4 Bone morphogenetic protein (BMP-9) promotes the calcification of VSMCs. VSMCs were incubated with BMP-9 (0.5–50 ng/ml) in high phos-
phate (P) (3 mM Pi) or control (C) (1 mM Pi) medium for 9 days. Calcium content was (A) visualized with alizarin red staining and (B) quantified
by HCL leaching (lg/mg protein; n = 5). Results are presented as mean  SEM. *P < 0.05; **P < 0.01; compared with 0 ng/ml BMP-9 treatment
or control.
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for the endothelial cell marker, CD31 (Fig. 2A). In addition, cells
showed positive staining for the smooth muscle cell marker SMA
(Green; Fig. 2A). FACs analysis further confirmed only 1.56% of iso-
lated cells positively stained for CD31 (Fig. 2B). Since AMC is highly
correlated with elevated serum phosphate levels, VSMCs were cul-
tured in growth medium containing high Pi (3 mM Pi). High Pi
induced a significant increase in VSMC calcium deposition (deter-
mined by HCL leaching and alizarin red staining) at day 7 and day 14,
compared to cells cultured in control medium (1 mM Pi; P < 0.001;
Fig. 2C).
A B C
D E F
G
Fig. 5 Effect of bone morphogenetic protein (BMP-9) treatment on the osteogenic marker expression. Fold change in the mRNA expression of osteo-
genic/osteocytic markers (A) Runx2, (B) Osx, (C) ALP, (D) PiT-1, (E) Mgp and (F) Sost (n = 4). Results are presented as mean  SEM. *P < 0.05;
**P < 0.01; ***P < 0.001 compared with corresponding 0 ng/ml BMP-9 treatment. (G) Sclerostin protein expression was increased following
BMP-9 treatment.
A B
Fig. 6 Critical role of alkaline phosphatase (ALP) in bone morphogenetic protein (BMP-9) induced VSMC calcification. (A) Quantification of alkaline
phosphatase activity (mean moles pNPP hydrol/min/mg protein in VSMCs incubated with BMP-9 (0.5–50 ng/ml) in high phosphate (3 mM Pi; filled
bar) or control (1 mM Pi; white bar) medium for 4 days (n = 5). (B) Calcium content was quantified by HCL leaching (lg/mg protein) in VSMCs
incubated with BMP-9 (50 ng/ml) in high phosphate (3 mM Pi) in the presence/absence of the ALP inhibitor DNB (3 lM; n = 5). Results are
presented as mean  SEM. *P < 0.05; ***P < 0.001 compared with 0 ng/ml BMP-9 treatment or control.
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Consistent with previous studies [4, 16, 19–21], high Pi induced
osteogenic transition of VSMCs, as demonstrated by significantly
up-regulated expression of Bmp2 (2.0-fold, P < 0.001; Fig. 3A),
Runx2 (2.1-fold, P < 0.001; Fig. 3B) and PiT-1 (1.7-fold, P < 0.001;
Fig. 3C) at 14 days. Interestingly, while a significant increase in
VSMC calcification was observed after 7 days of treatment with high
phosphate (Fig. 2C), increased expression of osteogenic markers was
only observed after 14 days of treatment. High phosphate may there-
fore initially regulate VSMC calcification through additional mecha-
nisms to the osteogenic differentiation of vascular cells, such as loss
of calcification inhibition, matrix degradation and apoptosis [2].
Having established basal levels of BMP9 expression in VSMCS
(Fig. 3D), BMP-9 mRNA expression (3.3-fold, P < 0.001; Fig. 3E)
was shown to be significantly increased at 14 days in VSMCs cul-
tured in calcifying medium. These data suggest that BMP-9 may be
actively involved in the calcification process.
BMP-9 induces osteogenic differentiation of
VSMCs and promotes high Pi-induced
calcification
To test whether BMP-9 directly regulates the osteogenic differentia-
tion and calcification of VSMCs, we treated cells with 0.5–50 ng/ml
BMP-9 in the presence or absence of high Pi medium for up to
9 days. In the presence of high Pi, a significant increase in calcium
deposition was observed following BMP-9 treatment at 50 ng/ml, as
determined by alizarin red staining and HCL leaching (3.4-fold;
P < 0.01; Fig. 4A and B). However, no increase in calcification was
observed under control Pi conditions (Fig. 4A and B). In the presence
of both high Pi and control conditions, a minimum concentration of
50 ng/ml BMP-9 treatment induced a significant increase in the
mRNA expression of the osteogenic markers Runx2, Osterix, Akp2,
PiT-1 and Sost (P < 0.05; Fig. 5A–E). Furthermore, a concomitant
reduction in the mRNA expression of the mineralization inhibitor Mgp
was observed following treatment of VSMCs with 50 ng/ml BMP-9
(P < 0.05; Fig. 5F). Comparable changes in sclerostin protein expres-
sion were also observed following treatment of VSMCs with 50 ng/ml
BMP-9 (Fig. 5G). These data suggest that BMP-9 directly induces
osteogenic differentiation of VSMCs, and subsequently increases the
susceptibility of VSMCs to calcification in the presence of high Pi.
In addition, treatment with BMP-9 for 4 days dose-dependently
induced ALP activity (2.7-fold at 5 ng/ml; P < 0.001; Fig. 6A) in both
high Pi and low Pi conditions. Interestingly, co-treatment of BMP-9
(50 ng/ml) with the ALP inhibitor DNB (3 lM) significantly reduced
the pro-calcificatory effects of BMP-9 (68%; P < 0.001; Fig. 6B).
BMP-9 signals through the ALK1 receptor to
promote VSMC calcification
RT-PCR revealed that both type I and type II BMP receptors (ALK1,
ALK2, BMPR-II, ActR-IIA and ActR-IIB) are expressed in cultured
murine VSMCs (Fig. 7A). It has been reported that BMP-9 prefers to
A B
C
Fig. 7 Effect of ALK-1 inhibition on bone
morphogenetic protein (BMP-9)-induced
VSMC calcification. (A) Expression of
BMP receptors in VSMCs cultured in high
phosphate (3 mM Pi; P) or control (1 mM
Pi; C) medium for 7 and 14 days. (B)
Quantification of alkaline phosphatase
activity (mean moles pNPP hydrol/min/mg
protein in VSMCs incubated with BMP-9
(50 ng/ml) in high phosphate (3 mM Pi;
filled bar) or control (1 mM Pi; white bar)
medium in the presence/absence of ALK1-
Fc (250 ng/ml and 1 lg/ml) for 4 days
(n = 5). (C) Calcium content was quanti-
fied by HCL leaching (lg/mg protein) in
VSMCs incubated with BMP-9 (50 ng/ml)
in high phosphate (3 mM Pi) in the pres-
ence/absence of the ALK1-Fc (250 ng/ml
and 1 lg/ml; n = 4). Results are pre-
sented as mean  SEM. **P < 0.01;
***P < 0.001.
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bind with ALK1 [22], therefore we next examined whether BMP-9-
induced ALP activity and calcification of VSMCs through the ALK1
receptor. ALK1-Fc (1 lg/ml), a soluble chimeric protein which com-
petitively binds ALK1 ligands [23], significantly inhibited BMP-9
(50 ng/ml) induced ALP activity (33%; P < 0.01; Fig. 7B) and mark-
edly reduced the pro-calcificatory actions of BMP-9 on VSMCs (85%;
P < 0.001; Fig. 7C). These data are the first to demonstrate that
BMP-9 signals via ALK1 to promote the osteogenic differentiation and
matrix calcification of VSMCs.
Intracellular signalling mechanisms mediating
BMP-9 induced VSMC calcification
To investigate the downstream intracellular signalling pathways,
VSMC were treated with BMP-9, and activation of Smads and Erk1/2
were assessed by western blotting and immunofluorescent staining.
BMP-9 dramatically induced the phosphorylation of Smad1/5/8 and
this phosphorylation was observed with concentrations as low as
0.5 ng/ml and reached maximum at 50 ng/ml. The translocation of
p-Smad1/5/8 to the nucleus was also observed following BMP-9
treatment (50 ng/ml). Furthermore, the phosphorylation of Smad2,
Smad3 and Erk1/2 was weakly induced by BMP-9 (Fig. 8A–C). Smad4
activation was not induced by BMP-9 at any concentration tested.
Smad1/5/8, Smad2 and Smad3 form complexes with the common-
partner Smad, Smad4. Transfection of VSMCs with Smad4 siRNA
resulted in an 80% reduction of Smad4 mRNA (P < 0.001) with a
comparable decrease in protein expression at 48 hrs post-transfection,
which was sustained to 96 hrs (Fig. S1A and B). While short-term
exposure of VSMCs to BMP-9 (10–60 min.) did not alter Smad4
expression, transfection of VSMCs with Smad4 siRNA significantly
inhibited BMP-9-induced ALP activity (72%; P < 0.001; Fig. 8D) and
markedly reduced the pro-calcificatory actions of BMP-9 on VSMCs
(61%; P < 0.001; Fig. 8E). These results are the first to show that
A B C
D
E
Fig. 8 Bone morphogenetic protein (BMP-9) induces VSMC calcification through activation of the Smad signalling pathway. Effect of (A) BMP-9 con-
centration (0.5–50 ng/ml) and (B) BMP-9 (50 ng/ml) exposure time (10–60 min) on the phosphorylation (p) of Smad1/5/8, Smad2, Smad3 and
Erk1/2 compared with total Smad1/5/8. (C) BMP-9-induced (0.5–50 ng/ml) nuclear translocation of phosphorylated Smad1/5/8, (Red). Areas within
white markings are shown under increased magnification. (D) Quantification of alkaline phosphatase activity (mean moles pNPP hydrol/min./mg pro-
tein in VSMCs transfected with Smad4 siRNA or Scramble control and incubated with BMP-9 (50 ng/ml) in high phosphate (3 mM Pi; filled bar) or
control (1 mM Pi; white bar) medium for 4 days (n = 5). (E) Calcium content was visualized with alizarin red staining and quantified by HCL leach-
ing (lg/mg protein) in VSMCs transfected with Smad4 siRNA or Scramble control and incubated with BMP-9 (50 ng/ml) in high phosphate (3 mM
Pi; n = 3). Results are presented as mean  SEM. *P < 0.05; **P < 0.01; ***P < 0.001 compared with corresponding Scramble control; scale
bar = 100 lm.
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BMP-9 signals through Smad4 to promote the osteogenic differentia-
tion and calcification of VSMCs.
Discussion
This study expands our current knowledge of the importance of BMP
signalling in vascular calcification. Here, we provide the first evidence
to suggest that BMP-9, one of the most osteogenic BMPs, also
contributes to this pathological process.
Investigations into the natural history of vascular calcification in
children with CKD have provided evidence that vessel wall calcifica-
tion begins pre-dialysis, with factors specific to the dialysis milieu
triggering accelerated calcification [3, 24]. Indeed, a number of urae-
mic toxins have been reported to accelerate vascular calcification in
vitro, including oxidized proteins [25, 26], phosphorus [27, 28], lipids
[29], parathyroid hormone-related peptide [30] and calcitriol [31].
Following reports that BMP-9 circulates under a biologically active
form [22] and is present in human serum [32], we sought to compare
BMP-9 levels in pre-dialysis and dialysis serum from children.
Remarkably, BMP-9 was notably elevated in serum from dialysis
patients. This may reflect increased BMP-9 production and/or
reduced clearance in the presence of severe kidney failure. While our
in vitro studies suggest that the circulating active form of BMP-9 is
locally activated in VSMCs, additional systemic sources cannot be
discounted. Interestingly, the most pronounced effects of BMP-9
administration in vitro were seen at concentrations 100-fold higher
than the serum BMP-9 concentrations noted in CKD dialysis patients.
This suggests potential enhancement of BMP-9 biological activity
in vivo. BMP-9 may therefore represent a novel kidney marker that
predicts progression to a major renal end-point. These findings are
further supported by previous reports highlighting disturbed concen-
trations of additional BMPs, including BMP2 and BMP7, in dialysis
patients [33–35].
Our subsequent in vitro investigations revealed that VSMCs cul-
tured with recombinant BMP-9 showed increased expression of
Runx2, Osterix, Akp2 and PiT-1, which are recognized regulators of
osteoblastic differentiation and matrix mineralization of VSMCs [4,
18, 36]. Furthermore, BMP-9 directly regulates the matrix minerali-
zation of VSMCs, through an ALP dependent mechanism involving
ALK1 receptor binding. ALP has been previously identified as a key
promoter of vascular calcification, via its ability to hydrolysis the
calcification inhibitor pyrophosphate [37]. In addition, our data sug-
gest that this process may be driven by increased PiT-1 expression
in the presence of elevated phosphate. These findings support previ-
ous data showing that ALK1-Fc inhibits BMP-9-mediated ALP
expression in C2C12 cells [38], and disclose for the first time the
use of the ALK1-Fc chimera to mediate significant loss of VSMC
calcification.
Mechanistically, our data suggest that BMP-9 stimulates the
phosphorylation of Smad1/5/8, which form a heterodimeric complex
with Smad4 in the nucleus and induces VSMC calcification. However,
potential synergy between BMP-9 and other TGFb superfamily mem-
bers expressed by VSMCs in response to phosphate treatment cannot
be discounted. This study highlights the Smad signalling pathway as
a hub in driving BMP-9 induced gene expression changes to initiate
aortic calcification. Our results compliment recent clinical studies
showing increased Smad1/5/8 phosphorylation in atherosclerotic
lesions and calcified aortic valves [39, 40] and data further suggest
that activation of Smad2, Smad3 and Erk1/2 pathways may refine the
effects of BMP-9 on VSMC calcification.
In conclusion, we have undertaken clinical analyses, in conjunc-
tion with in vitro VSMC calcification studies, to provide fundamental
insights into the role of BMP-9 as a potent osteogenic inducer of vas-
cular calcification. BMP-9 therefore appears to play a critical role in
vascular calcification. Further translational studies involving human
tissues are therefore required to assess whether BMP-9 may repre-
sent a novel potential therapeutic target for clinical intervention.
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